Effective upon publication of a final rule following a 30-day public comment period, the Drug Enforcement Administration (DEA) intends to temporarily classify 7-OH, a component of kratom with opioid-like effects, as a Schedule I controlled substance under the Controlled Substances Act. According to a draft notice of intent in the Federal Register scheduled for publication, the DEA asserts that 7-OH "presents severe risks to public health, including tolerance, dependence and addiction." Products containing 7-OH above a specific threshold would be subject to the ban, which will last for two years with the possibility of a third-year extension.
What Changed: Proposed Schedule I Classification
The DEA's action targets 7-OH, a chemically manipulated compound found in kratom that activates mu-opioid receptors in the brain, leading to its reputation as "gas station heroin." While natural kratom contains trace amounts of 7-OH, recent years have seen an explosion in unregulated 7-OH products such as gummies, drinks, and capsules sold in gas stations and smoke shops. The temporary ban would make 7-OH a Schedule I drug—the same category as heroin—imposing strict controls on its production, distribution, and possession.
Who Is Affected: Scope of Application
The ban applies to any entity handling 7-OH products that exceed the yet-to-be-specified threshold concentration. This includes manufacturers, distributors, retailers (including gas stations and smoke shops), and importers/exporters. The DEA has not yet published the exact threshold, but compliance will hinge on product testing and certification. The mainstream kratom industry, represented by the American Kratom Association, supports the ban, arguing that 7-OH is not natural kratom. Mac Haddow, senior fellow on public policy for the American Kratom Association, stated in a press release: "This DEA action should end the debate. Chemically manipulated 7-OH opioids are not kratom."
Conversely, the 7-OH industry is pushing back. Jeff Smith, executive director of the Holistic Alternative Recovery Trust, a 7-OH advocacy group, argued in an emailed statement: "Hundreds of thousands of consumers are eager to share how 7-OH has helped them manage pain, return to work, care for their families, and reclaim their life."
Compliance Obligations and Deadlines
Upon the ban's effective date (30 days after the notice is published), all entities must:
- Cease production, distribution, and sale of 7-OH products above the threshold unless registered with the DEA for research purposes.
- Implement security measures required for Schedule I substances, including storage in locked cabinets, inventory records, and reporting.
- Destroy existing stock or surrender it to the DEA within a specified timeframe.
- Ensure that import/export of 7-OH ceases immediately, as Schedule I substances generally cannot be imported or exported except under limited research exemptions.
The DEA has not yet announced a specific compliance deadline beyond the 30-day comment period. Trade compliance officers and customs brokers should monitor the Federal Register for the final rule and threshold details.
Penalties for Non-Compliance
The Controlled Substances Act imposes severe penalties for Schedule I violations. While the source does not specify exact fine amounts, unauthorized handling of Schedule I substances can lead to criminal prosecution, imprisonment, and substantial fines. Customs and border protection actions may include seizure of shipments and denial of entry.
Industry Reactions and Next Steps
The ban has divided stakeholders. The mainstream kratom industry, with political backing from President Donald Trump and ties to officials including Health and Human Services Secretary Robert F. Kennedy Jr. and Department of Homeland Security Secretary Markwayne Mullin (who invested up to $1 million in Botanic Tonics, a kratom drink company), hailed the move. One anonymous 7-OH user told WIRED she has already stockpiled a "formidable stash" in anticipation of the ban, stating that 7-OH allowed her to stop using other opioids.
The DEA will accept public comments for 30 days after the Federal Register notice. Companies affected by the proposed ban should submit comments and begin preparing for compliance given the limited timeline. Importers and exporters handling kratom-derived products should test their inventory for 7-OH content and assess supply chain impacts.
